Nikola (NKLA) : New companies entering the electric vehicle field muddies the race track. New comer NKLA has a long way to go, like years, before actually delivering on an electric vehicle on time and on budget. In the meantime? yea the monkeys can play.
Inovio (INO): I watch the major networks interview what they call "top doctors" on Corona vaccine progress. They all speak of the FOUR candidates and "promising" things coming. BUT not ONE mentioned Inovio. It seems in the near term "the fix"by the Trump OWS team is in and it's not Inovio at this present time. I somewhat fault Inovio for for not striking the PR world when the iron is hot. Waiting for a "peer review"? yea ok , whatever. I gave them my own review. I still hold some Inovio for the long term potential of the Brain and Cervical cancer pipeline - but their near term volatility and whipsaws down have soured me some on Inovio. I think Inovio PR has failed the little people that got shook out in order to "save themselves" in that last whip saw down. Waiting for one of the four horses to falter seems dicey if not faulty. I'm in a "few some shares" of INO, for now anyway.
Co-Diagnostics (CODX)
Motely fool had a decent article on CODX Co-Diagnostics (CODX) reported earnings and while a nice increase and positive, disappointed....
"Co-Diagnostics reported revenue in Q2 of $24 million and net income of $12.6 million, or $0.46 per diluted share. While those results reflected significant improvement over the prior-year period, they fell far short of what analysts were expecting. The consensus analysts' estimate projected revenue of $26.5 million and earnings of $0.59 per share."
https://www.fool.com/investing/2020/08/14/why-co-diagnostics-stock-is-tanking-today/
The Yale saliva test is in the news but the CODX is also FDA approved. Not having taken part in the whipsaw down makes me wonder if CODX is a buy opportunity. Hey, earnings of 46 cents a share were not too shabby.
__
ALL in my humble opinion, scroll down and read more..
This site does NOT make Buy / Sell recommendations.
___
